Literature DB >> 20797646

Guillain-Barré syndrome after exposure to influenza virus.

Helmar C Lehmann1, Hans-Peter Hartung, Bernd C Kieseier, Richard A C Hughes.   

Abstract

Guillain-Barré syndrome (GBS) is an acute, acquired, monophasic autoimmune disorder of peripheral nerves that develops in susceptible individuals after infection and, in rare cases, after immunisation. Exposure to influenza via infection or vaccination has been associated with GBS. We review the relation between GBS and these routes of exposure. Epidemiological studies have shown that, except for the 1976 US national immunisation programme against swine-origin influenza A H1N1 subtype A/NJ/76, influenza vaccine has probably not caused GBS or, if it has, rates have been extremely low (less than one case per million vaccine recipients). By contrast, influenza-like illnesses seem to be relevant triggering events for GBS. The concerns about the risk of inducing GBS in mass immunisation programmes against H1N1 2009 do not, therefore, seem justified by the available epidemiological data. However, the experiences from the 1976 swine flu vaccination programme emphasise the importance for active and passive surveillance to monitor vaccine safety. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20797646     DOI: 10.1016/S1473-3099(10)70140-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  52 in total

1.  Post-H1N1 narcolepsy-cataplexy.

Authors:  Yves Dauvilliers; Jacques Montplaisir; Valéerie Cochen; Alex Desautels; Mali Einen; Ling Lin; Minae Kawashima; Sophie Bayard; Christelle Monaca; Michel Tiberge; Daniel Filipini; Asit Tripathy; Bich Hong Nguyen; Suresh Kotagal; Emmanuel Mignot
Journal:  Sleep       Date:  2010-11       Impact factor: 5.849

2.  HLA-DRB1 the notorious gene in the mosaic of autoimmunity.

Authors:  María-Teresa Arango; Carlo Perricone; Shaye Kivity; Enrica Cipriano; Fulvia Ceccarelli; Guido Valesini; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

3.  Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.

Authors:  Rohit P Ojha; Bradford E Jackson; Joseph E Tota; Tabatha N Offutt-Powell; Karan P Singh; Sejong Bae
Journal:  Hum Vaccin Immunother       Date:  2013-09-06       Impact factor: 3.452

4.  Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study.

Authors:  Sara Ghaderi; Nina Gunnes; Inger Johanne Bakken; Per Magnus; Lill Trogstad; Siri Eldevik Håberg
Journal:  Eur J Epidemiol       Date:  2015-05-26       Impact factor: 8.082

5.  Cumulative risk of Guillain-Barré syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic.

Authors:  Claudia Vellozzi; Shahed Iqbal; Brock Stewart; Jerome Tokars; Frank DeStefano
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

Review 6.  Influenza.

Authors:  Timothy M Uyeki
Journal:  Ann Intern Med       Date:  2017-09-05       Impact factor: 25.391

7.  A 3-month-old baby with H1N1 and Guillain-Barré syndrome.

Authors:  Alexandra Vasconcelos; Francisco Abecasis; Rita Monteiro; Cristina Camilo; Marisa Vieira; Mamede de Carvalho; Manuela Correia
Journal:  BMJ Case Rep       Date:  2012-03-27

8.  Statement on Seasonal Influenza Vaccine for 2011-2012: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-10-14

Review 9.  Immune-mediated adverse reactions to vaccines.

Authors:  Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2019-11-05       Impact factor: 4.335

Review 10.  Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.

Authors:  Pallavi Asthana; Joaquim Si Long Vong; Gajendra Kumar; Raymond Chuen-Chung Chang; Gang Zhang; Kazim A Sheikh; Chi Him Eddie Ma
Journal:  Mol Neurobiol       Date:  2015-09-15       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.